Future-proofing the Biopharmaceutical QC Laboratory: Using the ACQUITY UPLC H-Class Bio System for HPLC Peptide Mapping

Significance of the Topic

Peptide mapping is a cornerstone of quality control in biopharmaceutical laboratories, enabling detailed characterization of protein therapeutics. Transitioning from conventional HPLC to UPLC promises enhanced reproducibility, higher resolution, and faster analyses, but presents challenges for laboratories bound by validated HPLC workflows and regulatory requirements.

Aims and Overview of the Study

This study demonstrates a straightforward approach for running established HPLC peptide mapping methods on the ACQUITY UPLC H-Class Bio System without altering chromatographic conditions. By simulating the dwell volume of legacy HPLC instruments through a gradient start offset, laboratories can validate new UPLC hardware while maintaining existing assay protocols.

Methodology

The method transfer was evaluated using three sample types: a MassPREP peptide mixture standard, trypsin-digested ribonuclease B, and trypsin-digested infliximab. All samples were prepared by reduction, alkylation, and overnight digestion with sequence-grade trypsin. Peptides were reconstituted in 5% acetonitrile/0.1% TFA and injected onto an XBridge BEH C18 130 Å, 4.6 × 100 mm, 3.5 μm column at 40 °C, 0.5 mL/min flow rate, using a gradient from 5% to 50% acetonitrile over 45 minutes. Chromatograms were recorded at 214 nm.

Used Instrumentation

• ACQUITY UPLC H-Class Bio System with Tunable UV (TUV) detector and 100 μL loop
• XBridge BEH C18 130 Å, 4.6 × 100 mm, 3.5 μm column
• Waters MassPREP peptide mixture standard
• Empower 3 chromatography data system

Main Results and Discussion

An initial direct transfer without modification produced earlier elution on the UPLC system due to lower dwell volume. Calculation of a 360 μL gradient start offset restored alignment of peptide peaks between UPLC and HPLC. When applied to the complex trypsinized ribonuclease B sample, retention time differences were under two seconds and relative retention time deviations below 0.01 for 33 monitored peaks. The approach was further validated with infliximab, where 56 selected peaks showed relative retention time differences below 0.005, confirming nearly identical chromatographic performance.

Benefits and Practical Applications of the Method

• Enables use of UPLC instrumentation for existing HPLC assays without redeveloping methods
• Reduces validation burden by simulating HPLC dwell volume via a simple gradient offset
• Facilitates step-wise migration to UPLC, minimizing workflow disruption
• Maintains regulatory compliance while introducing advanced chromatographic technology

Future Trends and Applications

As regulatory agencies increasingly recognize UPLC benefits for biopharmaceutical characterization, laboratories will progressively adopt UPLC-based methods. Future work will focus on full method optimization for UPLC separations, broader application to diverse biotherapeutics, and integration with high-resolution mass spectrometry for in-depth structural analysis.

Conclusion

The gradient start offset strategy offers a practical pathway for QC laboratories to future-proof peptide mapping workflows. By accounting for dwell volume differences, legacy HPLC methods run seamlessly on UPLC platforms, enabling gradual adoption of higher-performance separations with minimal disruption.

References

No external literature references were provided in the original text.